Objective: To observe the clinical efficacy and safety of regorafenib combined with immune checkpoint inhibitors in the treatment of patients with advanced colorectal cancer of pMMR/MSS type. Methods: 42 patients with advanced colorectal cancer of pMMR/MSS type admitted to the Department of Oncology of our hospital from January 2022 to September 2023 were randomly divided into the observation group and the control group, 21 cases each. The observation group was treated with the addition of regorafenib combined with immune checkpoint inhibitors, while the control group was given regorafenib monotherapy, and the efficacy, adverse effects, and survival of patients in the two groups were observed. Results: the total remission rate of the control group was 23.81%, and the total remission rate of the observation group was 57.14%, and the difference between the two groups was statistically significant (P < 0.05); there were 14 cases of adverse reactions in the two groups, with an incidence rate of 33.33% (14/42); and the overall survival rate of the observation and control groups was 71.43% and 47.62%, respectively. The survival rate of the observation group was higher than that of the control group, but the difference was not statistically significant (P > 0.05). Conclusion: Regorafenib combined with anti-PD-1 monoclonal antibody can significantly improve the efficacy and prognosis of advanced colorectal cancer without increasing adverse effects.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: